IMARC GroupÀº 2024³â ¼¼°è Ä¡¸Å Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð°¡ 196¾ï ´Þ·¯¿¡ ´ÞÇßÀ¸¸ç, 2025-2033³â ¿¬Æò±Õ ¼ºÀå·ü(CAGR)Àº 6.9%, 2033³â¿¡´Â 357¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀº ¼¼°è Àα¸ÀÇ °í·ÉÈ, Ä¡¸Å °ü·Ã Áúȯ¿¡ ´ëÇÑ Àνİú Áø´ÜÀÇ Áõ°¡, ¾ËÃ÷ÇÏÀ̸Ӻ´ ¹× ±âŸ Ä¡¸Å¿¡ ´ëÇÑ È¿°úÀûÀÎ Ä¡·á¹ýÀ» ¹ß°ßÇϱâ À§ÇÑ Áö¼ÓÀûÀÎ ¿¬±¸ °³¹ß·Î ÀÎÇØ ²ÙÁØÇÑ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù.
½ÃÀå ¼ºÀå°ú ±Ô¸ð¼¼°è Ä¡¸Å Ä¡·áÁ¦ ½ÃÀåÀº Ä¡¸Å °ü·Ã Áúȯ, ƯÈ÷ ¾ËÃ÷ÇÏÀ̸Ӻ´ÀÇ À¯º´·ü Áõ°¡¿¡ ÈûÀÔ¾î Å©°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ¼¼°è Àα¸ÀÇ °í·ÉÈ, ÀÎÁö±â´É ÀúÇϸ¦ °ü¸®Çϰí ȯÀÚÀÇ »îÀÇ ÁúÀ» Çâ»ó½ÃŰ´Â È¿°úÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ½ÃÀå ±Ô¸ð°¡ È®´ëµÇ°í ÀÖ½À´Ï´Ù.
±â¼ú ¹ßÀü: ½Å°æ¿µ»ó ±â¼ú, ¹ÙÀÌ¿À¸¶Ä¿ ½Äº°, Á¤¹ÐÀÇ·áÀÇ ¹ßÀüÀº Á¶±â Áø´Ü°ú ¸ÂÃãÇü Ä¡·á °èȹ¿¡ µµ¿òÀ» ÁÖ°í ÀÖ½À´Ï´Ù. ¿ø°ÝÀÇ·á¿Í µðÁöÅÐ Çコ Ç÷§ÆûÀº Ä¡¸Å ȯÀÚ¿Í °£º´ÀÎÀÇ ¿ø°Ý ¸ð´ÏÅ͸µ°ú Áö¿øÀ» °ÈÇϰí ÀÖ½À´Ï´Ù.
»ê¾÷ ÀÀ¿ë: Ä¡¸Å Ä¡·áÁ¦ ½ÃÀåÀº ÁÖ·Î Äݸ°¿¡½ºÅ×¶ó¾ÆÁ¦ ¾ïÁ¦Á¦, NMDA ¼ö¿ëü ±æÇ×Á¦ µî ÀǾàǰ¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù. ÀÎÁö ÀÚ±Ø ¿ä¹ýÀ̳ª Çൿ °ü¸® Àü·«°ú °°Àº ºñ¾à¸®ÇÐÀû °³ÀÔµµ Á߿伺ÀÌ Ä¿Áö°í ÀÖ½À´Ï´Ù.
Áö¸®Àû µ¿Çâ : ºÏ¹Ì¿Í À¯·´Àº Ä¡¸Å À¯º´·üÀÌ ³ô°í ¿¬±¸ ÀÎÇÁ¶ó°¡ Àß °®Ãß¾îÁ® ÀÖ¾î ½ÃÀåÀÌ Àß Çü¼ºµÇ¾î ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÅÈï ½ÃÀåÀº ÀÎ½Ä °³¼±°ú ÀÇ·á ÅõÀÚ·Î ÀÎÇØ ºü¸£°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù.
°æÀï »óȲ : ½ÃÀåÀº ÁÖ¿ä ±â¾÷µéÀÌ ±â¼ú Çõ½Å, ÀμöÇÕº´(M&A), ¼¼°è ÁøÃâ¿¡ ÁýÁßÇÏ´Â Ä¡¿ÇÑ °æÀïÀÌ Æ¯Â¡ÀÔ´Ï´Ù. Á¦¾à±â¾÷µéµµ °æÀï·ÂÀ» ³ôÀ̱â À§ÇØ ¿¬±¸°³¹ß¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù.
µµÀü°ú ±âȸ : µµÀüÀº ³ôÀº ÀǾàǰ °³¹ß ºñ¿ë, ±ÔÁ¦ À庮, Àå±âÀûÀÎ ÀÓ»ó½ÃÇèÀÇ Çʿ伺 µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. ±âȸ´Â Á¶±â Áø´Ü, ½Å¾à ¹ß°ß, ºñ¾à¸®ÇÐÀû ÁßÀç¿¡ ÀÖ½À´Ï´Ù.
ÇâÈÄ Àü¸Á : Ä¡¸Å Ä¡·áÁ¦ ½ÃÀåÀº Áúº´ Á¶Àý ¿ä¹ý°ú ¸ÂÃãÇü ÀÇ·á¿¡ ÁßÁ¡À» µÎ°í Áö¼ÓÀûÀÎ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ½Å°æ ¿µ»ó Áø´Ü, ¹ÙÀÌ¿À¸¶Ä¿ ½Äº°, ¿ø°ÝÀÇ·á µîÀÇ ¹ßÀüÀÌ Ä¡¸Å Ä¡·áÀÇ ¹Ì·¡¸¦ Çü¼ºÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
Àα¸ °í·ÉÈ
Ä¡¸Å Ä¡·áÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎ Áß Çϳª´Â ¼¼°è Àα¸ÀÇ °í·ÉÈÀÔ´Ï´Ù. »ç¶÷µéÀÌ ¿À·¡ »ì¼ö·Ï Ä¡¸Å¿Í °°Àº ³ëÈ °ü·Ã ÁúȯÀÇ ¹ß»ý·üÀº ´ç¿¬È÷ Áõ°¡ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Àα¸Åë°èÇÐÀû º¯È·Î ÀÎÇØ Ä¡¸Å °ü·Ã ÀÇ·á ¼ºñ½º ¹× ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)ÀÇ º¸°í¿¡ µû¸£¸é, 60¼¼ ÀÌ»ó Àα¸´Â 2050³â±îÁö µÎ ¹è·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ³ëÀÎ Àα¸ÀÇ Áõ°¡´Â Ä¡¸Å À¯º´·üÀÇ ±Þ°ÝÇÑ Áõ°¡·Î À̾îÁú °¡´É¼ºÀÌ ³ôÀ¸¸ç, ÀÌ¿¡ µû¶ó È¿°úÀûÀÎ Ä¡¸Å Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
±â¼ú ¹ßÀü
Ä¡¸Å Ä¡·áÁ¦ ½ÃÀåÀº ÀǾàǰ ¿¬±¸ ¹× °³¹ßÀÇ ´«ºÎ½Å ¹ßÀü¿¡ ÈûÀÔ¾î ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. Ä¡¸ÅÀÇ ¹è°æÀÌ µÇ´Â ½Å°æ»ý¹°ÇÐÀû ¸ÞÄ¿´ÏÁò¿¡ ´ëÇÑ ÀÌÇØ°¡ ±í¾îÁü¿¡ µû¶ó, Á¦¾àȸ»çµéÀº º¸´Ù È¿°úÀûÀ̰í Ç¥ÀûÈµÈ ¾à¹° °³¹ß¿¡ Á¡Á¡ ´õ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀü¿¡´Â °¡Àå ÈçÇÑ Ä¡¸ÅÀÎ ¾ËÃ÷ÇÏÀ̸Ӻ´ÀÇ ¹ßº´¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â °ÍÀ¸·Î ¿©°ÜÁö´Â ¾Æ¹Ð·ÎÀ̵å ÇöóÅ©¿Í Ÿ¿ì ´Ü¹éÁú°ú °°Àº »õ·Î¿î Ä¡·á Ç¥Àû¿¡ ´ëÇÑ Å½»öµµ Æ÷ÇԵ˴ϴÙ. ¶ÇÇÑ ¾çÀüÀÚ¹æ»ç´ÜÃþÃÔ¿µ(PET), ÀÚ±â°ø¸í¿µ»ó(MRI) µî ½Å°æ¿µ»ó ±â¼úÀÇ ¹ßÀüÀ¸·Î Ä¡¸Å °ü·Ã ÁúȯÀÇ º¸´Ù Á¤È®ÇÑ Áø´Ü°ú ¸ð´ÏÅ͸µÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. ¶ÇÇÑ, ¹ÙÀÌ¿À¸¶Ä¿ÀÇ ½Äº°°ú À¯ÀüÀÚ ¿¬±¸´Â Á¤¹ÐÀÇ·á Á¢±Ù¹ýÀÇ °³¹ßÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ½Å¾à°³¹ß, ÀÓ»ó½ÃÇè ¼³°è, ¿ø°ÝÀÇ·áÀÇ ±â¼ú Çõ½Åµµ Ä¡¸Å Ä¡·áÁ¦ °³¹ß°ú ȯÀÚ Ä¡·áÀÇ È¿À²¼ºÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù.
ÀÎÁöµµ Çâ»ó ¹× Á¶±â Áø´Ü
Ä¡¸Å¿Í ±× Áõ»ó¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼ Á¶±â Áø´Ü°ú Á¶±â Ä¡·á·Î À̾îÁö°í ÀÖ½À´Ï´Ù. °øÁߺ¸°Ç Ä·ÆäÀΰú ±³À° ÀÌ´Ï¼ÅÆ¼ºê´Â Ä¡¸ÅÀÇ Ãʱâ Áõ»ó¿¡ ´ëÇÑ ÀνÄÀ» ³ôÀÌ°í »ç¶÷µéÀÌ ´õ »¡¸® ÀÇ»çÀÇ Áø´ÜÀ» ¹Þµµ·Ï Àå·ÁÇϰí ÀÖ½À´Ï´Ù. Á¶±â Áø´ÜÀº Àû½Ã¿¡ °³ÀÔÇϰí Áúº´ÀÇ ÁøÇàÀ» ´ÊÃâ ¼ö Àֱ⠶§¹®¿¡ Ä¡¸Å¸¦ È¿°úÀûÀ¸·Î °ü¸®ÇÏ´Â µ¥ ÀÖ¾î ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÀνÄÀÇ Áõ°¡¿Í Áø´Ü ±â¼úÀÇ ¹ßÀüÀº Ä¡¸Å Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù.
ÀÇ·áºñ ÁöÃâ Áõ°¡
Àü ¼¼°è ÀÇ·áºñ ÁöÃâ Áõ°¡µµ Ä¡¸Å Ä¡·áÁ¦ ½ÃÀåÀ» °ßÀÎÇÏ´Â ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. Á¤ºÎ¿Í ÀÇ·á ±â°üÀº Ä¡¸Å¸¦ Æ÷ÇÔÇÑ ¸¸¼ºÁúȯÀÇ °ü¸® ¹× Ä¡·á¿¡ ¸¹Àº ÀÚ¿øÀ» ÇÒ´çÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÚ±Ý Áõ°¡´Â ¿¬±¸, ÀǾàǰ °³¹ß, Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ Á¢±Ù¼º Çâ»óÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·á ÀÎÇÁ¶ó¿Í ¼ºñ½º¸¦ °³¼±ÇÏ¿© Ä¡¸ÅÀÇ Áõ»ó°ú ÁøÇàÀ» ´õ Àß °ü¸®ÇÏ·Á´Â ±¤¹üÀ§ÇÑ ³ë·ÂÀ» ¹Ý¿µÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¤ºÎ, ÀÇ·á´Üü, ¿ËÈ£´ÜüµéÀº Ä¡¸Å¿¡ ´ëÇÑ ´ëÀÀÀÌ ½Ã±ÞÇÏ´Ù´Â °ÍÀ» ÀνÄÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀνÄÀº ¿¬±¸¿¡ ´ëÇÑ ÀÚ±Ý Áö¿øÀ» ÃËÁøÇϰí, ÀǾàǰ Çõ½ÅÀ» ÃËÁøÇϴ ȯ°æÀ» Á¶¼ºÇϰí ÀÖ½À´Ï´Ù.
The global dementia drugs market size reached USD 19.6 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 35.7 Billion by 2033, exhibiting a growth rate (CAGR) of 6.9% during 2025-2033. The market is experiencing steady growth driven by aging global population, increasing awareness and diagnosis of dementia-related conditions, and ongoing research and development efforts to discover effective treatments for Alzheimer's disease and other forms of dementia.
Market Growth and Size: The global dementia drugs market is experiencing significant growth, driven by the increasing prevalence of dementia-related conditions, particularly Alzheimer's disease. Market size is expanding due to the aging global population and the rising demand for effective treatments to manage cognitive decline and improve the quality of life for patients.
Technological Advancements: Advances in neuroimaging technologies, biomarker identification, and precision medicine are aiding in early diagnosis and personalized treatment plans. Telemedicine and digital health platforms are enhancing remote monitoring and support for dementia patients and caregivers.
Industry Applications: The dementia drugs market is primarily focused on pharmaceuticals, including cholinesterase inhibitors and NMDA receptor antagonists. Non-pharmacological interventions, such as cognitive stimulation therapies and behavioral management strategies, are also gaining importance.
Geographical Trends: North America and Europe have well-established markets due to a higher prevalence of dementia and strong research infrastructure. Emerging markets in Asia-Pacific are experiencing rapid growth due to increasing awareness and healthcare investments.
Competitive Landscape: The market is characterized by intense competition with key players focusing on innovation, mergers and acquisitions (M&A), and expanding their global footprint. Pharmaceutical companies are also investing heavily in research and development to gain a competitive edge.
Challenges and Opportunities: Challenges include the high cost of drug development, regulatory hurdles, and the need for long-term clinical trials. Opportunities lie in early diagnosis, novel drug discovery, and non-pharmacological interventions.
Future Outlook: The dementia drugs market is poised for continued growth with a focus on disease-modifying therapies and personalized medicine. Advances in neuroimaging, biomarker identification, and telemedicine are expected to shape the future of dementia care.
Ageing population
One of the primary drivers of the dementia drugs market is the aging global population. As people live longer, the incidence of age-related diseases like dementia naturally increases. This demographic shift results in a higher demand for dementia-related healthcare services and medications. The World Health Organization reports that the number of people aged 60 years and older is expected to double by 2050. This increase in the elderly population is likely to lead to a surge in the prevalence of dementia, thereby fueling the demand for effective dementia drugs.
Technological Advancements
The dementia drugs market is also driven by significant advancements in pharmaceutical research and development. With a better understanding of the neurobiological mechanisms behind dementia, pharmaceutical companies are increasingly investing in the development of more effective and targeted drugs. These advancements include the exploration of new therapeutic targets, such as amyloid plaques and tau proteins, which are believed to play a crucial role in the development of Alzheimer's disease, the most common form of dementia. Besides, advances in neuroimaging technologies, such as positron emission tomography (PET) and magnetic resonance imaging (MRI), enable more accurate diagnosis and monitoring of dementia-related conditions. Additionally, biomarker identification and genetic research are driving the development of precision medicine approaches. Technological innovations in drug discovery, clinical trial design, and telemedicine are also enhancing the efficiency of dementia drug development and patient care.
Increasing awareness and early diagnosis
There is a growing awareness about dementia and its symptoms, leading to earlier diagnosis and treatment. Public health campaigns and educational initiatives are increasing awareness of dementia's early signs, encouraging people to seek medical advice sooner. Early diagnosis is crucial in managing dementia effectively, as it allows for timely intervention and slows the progression of the disease. This growing awareness, coupled with improvements in diagnostic techniques, is driving the demand for dementia drugs.
Rising healthcare expenditure
Increasing healthcare expenditure globally is another factor boosting the dementia drugs market. Governments and healthcare organizations are allocating more resources to manage and treat chronic conditions, including dementia. This increased funding supports research, drug development, and improved access to treatment options. It also reflects a broader commitment to enhancing healthcare infrastructure and services, thereby facilitating better management of dementia symptoms and progression. Besides, governments, healthcare organizations, and advocacy groups are increasingly recognizing the urgency of addressing dementia. This recognition is driving funding for research and creating an environment conducive to pharmaceutical innovation.
Lewy Body Dementia
Parkinson's Disease Dementia
Alzheimer's Disease
Vascular Dementia
Others
Alzheimer's disease accounts for the majority of the market share
Cholinesterase Inhibitors
NMDA Antagonists and its Combination Drugs
Cholinesterase inhibitors holds the largest share in the industry
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Hospital pharmacies represents the leading market segment
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America leads the market, accounting for the largest dementia drugs market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:
Abbvie Inc.
Apotex Inc.
Biogen Inc.
Eisai Co. Ltd.
Johnson & Johnson
Merck & Co. Inc.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.